The efficacy of three antihypertensive treatments given for 3 weeks each, 2.5 mg cilazapril, a new potent long-acting angiotensin-converting enzyme (ACE) inhibitor, 120 mg propranolol, and the combination of both, were compared in 17 patients suffering from essential hypertension. Blood pressure control (i.e. sitting diastolic blood pressure at rest less than or equal to 90 mm Hg) was achieved in about 40% of the patients by the monocomponents, the combination therapy increased the rate to 80%. An additional blood pressure-lowering effect of the combination was also observed during isometric exercise (handgrip) but not during isotonic exercise (bicycle). At rest and during isometric exercise on cilazapril alone cardiac output rose, total peripheral resistance fell, on propranolol the inverse reactions occurred. On the combination cardiac output and total peripheral resistance decreased. During isotonic exercise propranolol slightly decreased (VO2max fell, lactate concentration went up), cilazapril slightly increased aerobic capacity (VO2max went up and lactate concentration fell) and exercise tolerance. These effects were partially attenuated by the combination. The additional blood pressure-lowering effect of the combination was assumed to be due to the suppression of the renin-angiotensin-aldosterone system (the ACE inhibitor and the betablocker act in a synergistic way), a peripheral vasodilation, and the reduction of sympathetic tone expressed as heart rate reduction and hence a decrease in cardiac output. It is concluded that the combination of an ACE inhibitor and a betablocker seems to exert a good antihypertensive activity not only at rest but also during exercise.
Download full-text PDF |
Source |
---|
J Nutr Educ Behav
January 2025
Suvida Healthcare, Houston, TX.
Objective: Assess if a virtual culinary medicine program improves healthy eating, glycosylated hemoglobin (HbA1c), and associated variables among adults with type 2 diabetes.
Design: Mixed-methods, intervention-only pilot study.
Setting: Classes via video conferencing from the teaching kitchen, with participants cooking from their homes.
Res Social Adm Pharm
January 2025
Department of Pharmacy Practice and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, University of Ghana, P. O. Box LG 43, Legon, Ghana. Electronic address:
Background: Patients with hypertension and other comorbidities have difficulties adhering to their medications which have negative impacts on clinical outcomes. Although some studies have identified strategies to improve medication adherence, a thorough analysis of these interventions will provide synthesized evidence for clinical decision-making and improved health outcomes for patients with hypertension comorbidities.
Aim: To conduct a scoping review on interventions that have been utilised to improve medication adherence in patients with hypertension and other co-morbid conditions.
J Formos Med Assoc
January 2025
Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:
Controlling hypertension has become an important issue in the elderly population in whom neurological comorbidities are highly prevalent. Most of the large-scale trials focusing on hypertension management in older populations have excluded patients with comorbid neurological disorders. However, this population requires special considerations, as the benefits of antihypertensive agents are mostly uncertain and there is a higher risk of adverse events.
View Article and Find Full Text PDFJ Am Soc Echocardiogr
January 2025
Cardiology Clinic, University Center Serbia, Medical School, University Clinical Center Serbia, University of Belgrade, Serbia.
Background: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous entity including patients with different phenotypes of near normal, normal, and supernormal left ventricular (LV) function.
Objectives: To assess the value of resting LV elastance (also known as force) with transthoracic echocardiography (TTE) to identify HFpEF phenotypes.
Methods: In a prospective, observational, multicenter study, 2380 HFpEF patients were recruited from July 2016 to May 2024.
Ann Endocrinol (Paris)
January 2025
Assistance Publique Hôpitaux de Paris, Pituitary Unit, Pitié-Salpêtrière Hospital, 75013 Paris, France. Electronic address:
Background: Non-functional adrenal incidentaloma (NFAI) is associated with increased risk of adverse cardiometabolic outcome. Identifying predictors of atherosclerotic cardiovascular disease (ASCVD) may enable more appropriate management strategies in patients with NFAI. We aimed to investigate body composition parameters and ASCVD risk in patients with NFAI.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!